Total (N = 133) | PA ≤ 6.47% (n = 60) | PA > 6.47% (n = 73) | P-value | |
---|---|---|---|---|
Demographics | ||||
Age, years | 79.52 ± 3.68 | 79.86 ± 3.76 | 79.23 ± 3.62 | 0.325 |
Male, n(%) | 99 (74.4) | 46 (76.7) | 53 (72.6) | 0.691 |
BMI, Kg/m2 | 23.17 ± 2.90 | 23.42 ± 2.93 | 23.00 ± 2.87 | 0.371 |
NYHA III/IV, n(%) | 83 (62.4) | 42 (50.6) | 41 (49.4) | 0.109 |
PA,% | 7.85 ± 4.64 | 3.99 ± 1.77 | 11.03 ± 3.77 | < 0.001 |
CRT-D, n(%) | 34 (25.6) | 17 (28.3) | 17 (23.3) | 0.553 |
Primary prevention, n(%) | 66 (49.6) | 29 (48.3) | 37 (50.7) | 0.862 |
Comorbidities | ||||
ICM, n(%) | 69 (51.9) | 32 (53.3) | 37 (50.7) | 0.862 |
HTN, n(%) | 62 (46.6) | 24 (40.0) | 38 (52.1) | 0.221 |
DM, n(%) | 21 (15.8) | 14 (23.3) | 7 (9.6) | 0.034 |
Stroke, n(%) | 5 (3.8) | 3 (5.0) | 2 (2.7) | 0.657 |
AF, n(%) | 17 (12.8) | 8 (13.3) | 9 (12.3) | 1.000 |
Syncope, n(%) | 27 (20.3) | 14 (23.3) | 13 (17.8) | 0.517 |
Echocardiography | ||||
LVEF, % | 42.00 ± 13.53 | 41.90 ± 14.25 | 42.09 ± 13.00 | 0.936 |
LVEDD, mm | 58.13 ± 11.62 | 56.47 ± 10.13 | 59.50 ± 12.61 | 0.134 |
Medication | ||||
ACEI/ARB, n(%) | 55 (41.4) | 27 (45.0) | 28 (38.4) | 0.482 |
β-blocker, n(%) | 70 (52.6) | 29 (48.3) | 41 (56.2) | 0.388 |
Amiodarone, n(%) | 39 (29.3) | 18 (30.0) | 21 (28.8) | 1.000 |
Diuretic, n(%) | 53 (39.8) | 28 (46.7) | 25 (34.2) | 0.159 |